Pemvidutide - Altimmune
Alternative Names: ALT-801- Altimmune; SP-1373; VPD-107Latest Information Update: 07 Oct 2024
At a glance
- Originator Velocity Pharmaceutical Development
- Developer Altimmune; Velocity Pharmaceutical Development
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis; Obesity
- Phase I Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Preclinical Dyslipidaemias; Hepatic fibrosis
Most Recent Events
- 30 Sep 2024 Altimmune plans to file IND applications for pemvidutide in three additional indications in Q4 2024
- 30 Sep 2024 Altimmune plans to initiate clinical trial for additional indication in H1 2025
- 30 Sep 2024 Altimmune completes enrolment in a phase II trial in Non-alcoholic steatohepatitis in USA, Puerto Rico and Australia (SC) (NCT05989711)